Drug Profile
Technetium-99m P 2045
Alternative Names: Tc-99m-P2045Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Andarix Pharmaceuticals
- Class Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (Parenteral)